SCHEMBL10180879

SCHEMBL10180879

C=CC(=O)Oc1cccc(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 4/20 0.43
THRA P10827 1/20 0.43
TYMS P04818 1/20 0.41
CES2 O00748 3/20 0.41
CES1 P23141 3/20 0.41
BCHE P06276 1/20 0.41
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HSD17B10 Q99714 1/20 0.40
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KMT2A Q03164 3/20 0.37
SLC2A1 P11166 1/20 0.36
SLC2A4 P14672 1/20 0.36
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ACHE P22303 1/20 0.33
EGFR P00533 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2933377 0.85 THRB (0.49) THRBTHRATYMSCES2CES1
SCHEMBL30596839 0.85 THRB (0.49) THRBTHRATYMSCES2CES1
SCHEMBL28900006 0.84 THRB (0.42) THRBTHRATYMSMAPTHPGD
SCHEMBL27760133 0.84 CES2 (0.42) CES2CES1BCHEMAPTHPGD
Hydrochloric Acid SCHEMBL28527576 0.84 THRB (0.48) THRBTHRATYMSCES2CES1
SCHEMBL30596845 0.84 CES2 (0.39) THRBTHRATYMSCES2CES1
SCHEMBL10180529 0.84 CES2 (0.39) THRBTHRATYMSCES2CES1
SCHEMBL13986530 0.83 TYMS (0.43) THRBTHRATYMSMAPTHPGD
SCHEMBL5690942 0.79 KMT2A (0.41) THRBTHRATYMSCES2CES1
SCHEMBL28936574 0.79 THRB (0.42) THRBTHRATYMSCES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2837671-B1 Liquid crystalline medium MERCK PATENT GMBH (DE) 2017-10-25 EP disclosed
US-20170044437-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2017-02-16 US disclosed
CN-105566021-A Preparation method of alpha, beta-unsaturated carboxylic acid compounds UNIV SCIENCE & TECH CHINA 2016-05-11 CN disclosed
CN-104112870-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEM CORP 2014-10-22 CN disclosed
US-20130244122-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME ONUKI MASAMICHI (JP) 2013-09-19 US disclosed
US-20120219866-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 US disclosed
EP-2475041-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME Mitsubishi Chemical Corporation (JP) 2012-07-11 EP disclosed
CN-102484281-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEM CORP 2012-05-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044437-A1 LIQUID-CRYSTALLINE MEDIUM VIM, COL2A1, COL1A1 THRB 3914/4885THRA 3589/4885TYMS 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.